Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Lerner

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Critical Reviews in Oncology/Hematology|March 1, 2022
Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myelomaCharles J Milrod, Michael Mann, Frances Blevins, et al.
Cancer Research|October 30, 2003
AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoterDongpo Cai, Anita Iyer, Kyriacos N Felekkis, et al.
Molecular Vision|April 15, 2009
Loss of AND-34/BCAR3 expression in mice results in rupture of the adult lensRichard I Near, Richard S Smith, Paul A Toselli, et al.
Leukemia & Lymphoma|August 31, 2017
Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapyMadeleine Duvic, Susan E Bates, Richard Piekarz, et al.
American Journal of Clinical Pathology|July 19, 2020
SARS-CoV-2 Infection-Associated Hemophagocytic LymphohistiocytosisAndrey Prilutskiy, Michael Kritselis, Artem Shevtsov, et al.
Leukemia & Lymphoma|March 21, 2015
Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphomaEllen J Kim, Youn H Kim, Alain H Rook, et al.
Blood Advances|September 30, 2024
Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosisMaya Abdallah, Frances Arters, Jasmine Patel, et al.
International Immunopharmacology|June 16, 2016
Anti-inflammatory effects of novel barbituric acid derivatives in T lymphocytesChenjia Xu, Arlene R Wyman, Manal A Alaamery, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 27, 2025
When ICAN(S) Becomes ICAN'T: Clinician and Staff Perspectives on In-Hospital Neurotoxicity GradingGrace M Ferri, Allison Frank, Daniel Li, et al.
Biomarker Research|October 4, 2014
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphomaFrancine Foss, Bertrand Coiffier, Steven Horwitz, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Critical Reviews in Oncology/Hematology|March 1, 2022
Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myelomaCharles J Milrod, Michael Mann, Frances Blevins, et al.
Cancer Research|October 30, 2003
AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoterDongpo Cai, Anita Iyer, Kyriacos N Felekkis, et al.
Molecular Vision|April 15, 2009
Loss of AND-34/BCAR3 expression in mice results in rupture of the adult lensRichard I Near, Richard S Smith, Paul A Toselli, et al.
Leukemia & Lymphoma|August 31, 2017
Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapyMadeleine Duvic, Susan E Bates, Richard Piekarz, et al.
American Journal of Clinical Pathology|July 19, 2020
SARS-CoV-2 Infection-Associated Hemophagocytic LymphohistiocytosisAndrey Prilutskiy, Michael Kritselis, Artem Shevtsov, et al.
Leukemia & Lymphoma|March 21, 2015
Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphomaEllen J Kim, Youn H Kim, Alain H Rook, et al.
Blood Advances|September 30, 2024
Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosisMaya Abdallah, Frances Arters, Jasmine Patel, et al.
International Immunopharmacology|June 16, 2016
Anti-inflammatory effects of novel barbituric acid derivatives in T lymphocytesChenjia Xu, Arlene R Wyman, Manal A Alaamery, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 27, 2025
When ICAN(S) Becomes ICAN'T: Clinician and Staff Perspectives on In-Hospital Neurotoxicity GradingGrace M Ferri, Allison Frank, Daniel Li, et al.
Biomarker Research|October 4, 2014
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphomaFrancine Foss, Bertrand Coiffier, Steven Horwitz, et al.
Pageof 7